Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MoonLake Immunotherapeutics filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing sonelokimab (SLK) for inflammatory diseases. Form 8-K reports cover operating and financial results, clinical-trial disclosures for SLK programs, FDA meeting updates, Regulation FD communications, material agreements and capital-structure matters involving Class A ordinary shares.
Proxy materials describe annual meeting voting matters, including director elections, auditor ratification, executive compensation and amendments to the 2022 Equity Incentive Plan. The filing record also includes exhibits and registration-related disclosures tied to financings, governance matters and shareholder approvals.
Jerucon Beratungsgesellschaft mbH filed a Form 144 notice covering the proposed sale of 150,000 Class A Ordinary shares of MLTX. The shares are to be sold through UBS Financial Services, Inc. on or after 07/15/2026 on the Nasdaq market for an aggregate value of 2916000.00.
The notice also reports that Jerucon Beratungsgesellschaft mbH has recently sold 50,000 common shares on each of 06/15/2026, 06/16/2026, and 06/17/2026, for aggregate proceeds of 944280.00, 934995.00, and 971325.00, respectively.
MoonLake Immunotherapeutics reported that underwriters in its previously announced public offering exercised in full their option to purchase an additional 1,500,000 Class A ordinary shares on July 10, 2026. The sale of these Option Shares generated $30.0 million in additional gross proceeds, before underwriting discounts, commissions and offering expenses. The issuance and sale of the Option Shares closed on July 14, 2026.
MoonLake Immunotherapeutics Chief Executive Officer Jorge Santos da Silva reported open‑market sales of Class A ordinary shares. On July 9 and 10, 2026, he sold a total of 102,225 shares at weighted average prices around $20.01–$20.02 per share under a pre‑arranged Rule 10b5‑1 trading plan adopted on March 31, 2026.
Following these transactions, he directly holds 2,774,893 Class A ordinary shares. The reported prices reflect weighted averages across multiple trades within narrow intraday ranges, with detailed per‑trade information available upon request from the issuer, the SEC staff, or a security holder.
MoonLake Immunotherapeutics director and Chief Executive Officer Jorge Santos da Silva sold 47,775 Class A ordinary shares in an open-market transaction at a weighted average price of $20.03 per share. The sale was executed on July 1, 2026 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
Following this transaction, he directly holds 2,877,118 Class A ordinary shares. The filing notes that the reported price reflects a weighted average across multiple individual trades executed between $20.00 and $20.09 per share.
MLTX Rule 144 notice reports proposed resale activity for Class A Ordinary shares. The filing lists 150,000 shares as the securities to be sold and shows a contemporaneous sale of 150,000 shares by Jorge Santos da Silva on 04/10/2026 for $2,787,000.00. The securities are listed on Nasdaq and the filing references an earlier exchange date of 04/05/2023.
MoonLake Immunotherapeutics’ major shareholder group BVF has updated its ownership disclosure in Amendment No. 6 to its Schedule 13D. The amendment reflects that BVF-affiliated funds and accounts beneficially own 16,001,284 Class A ordinary shares, representing about 19.7% of MoonLake’s 81,134,066 shares outstanding as of June 25, 2026, following a recent offering.
The filing also notes director Spike Loy’s beneficial ownership of 25,667 shares through options exercisable within sixty days. On June 17, 2026, he was granted stock options to purchase 22,195 shares at an exercise price of $19.19 per share, vesting by June 17, 2027 or the next annual meeting and expiring on June 17, 2036.
MoonLake Immunotherapeutics entered an underwriting agreement for a $200 million equity offering. The company agreed to sell 9,000,000 Class A ordinary shares at $20.00 per share and, for certain investors, pre-funded warrants to purchase up to 1,000,000 ordinary shares at a public offering price of $19.9999 each with a nominal exercise price of $0.0001.
The underwriters also have a 30-day option to buy up to an additional 1,500,000 ordinary shares at the public offering price less underwriting discounts and commissions. The securities are being issued under an effective Form S-3 shelf registration, with closing expected on June 25, 2026, subject to customary conditions.
MoonLake Immunotherapeutics is conducting a registered offering of 9,000,000 Class A Ordinary Shares and, in lieu of shares to certain investors, pre-funded warrants to purchase up to 1,000,000 Class A Ordinary Shares at a public offering price of $20.00 per share. Delivery is expected on June 25, 2026. The prospectus estimates net proceeds of approximately $188.8 million (or about $217.1 million if the underwriters’ option to purchase up to 1,500,000 additional shares is exercised in full). Proceeds are planned to fund development, pre-commercialization and potential commercialization of Sonelokimab (“SLK”), with stated runway to mid-2028 if approved and assuming current plans. The offering includes customary underwriting discounts and a lock-up period for certain insiders.
MoonLake Immunotherapeutics’ Chief Financial Officer Matthias Bodenstedt reported an open-market sale of 39,120 Class A ordinary shares on June 22, 2026. The shares were sold at a weighted average price of $22.04 per share, in multiple trades between $19.87 and $23.2049. Following the sale, he directly holds 1,115,435 shares, so the transaction represents a small portion of his stake. The sale was executed under a pre-arranged Rule 10b5‑1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance.
MoonLake Immunotherapeutics is offering securities under a preliminary prospectus supplement for an aggregate offering amount of $150,000,000. The offering covers Class A Ordinary Shares and, in lieu of shares for certain investors, pre-funded warrants exercisable at $0.0001 per share. The underwriters have a 30‑day option to purchase up to $22,500,000 of additional Class A Ordinary Shares. The prospectus cites 72,134,066 Class A Ordinary Shares outstanding as of March 31, 2026 and discloses a last reported Nasdaq sale price of $22.16 on June 22, 2026. Net proceeds are intended to fund continued development and (if approved) commercialization of SLK (Sonelokimab) and for general corporate purposes. The prospectus supplement notes clinical Phase 3 VELA program results for SLK in hidradenitis suppurativa and discusses risks, dilution, PFIC tax considerations and limits on pre-funded warrant exercisability.